SXI Life Sciences
|
7 735,02
|
16,04
|
0,21 %
|
Analysen zu SXI Life Sciences-Werten
| 12.03.24 | Roche Equal Weight | Barclays Capital | |
| 26.02.24 | Roche Hold | Jefferies & Company Inc. | |
| 22.02.24 | Roche Neutral | UBS AG | |
| 21.02.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 20.02.24 | Roche Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 07.02.24 | Novartis Buy | Deutsche Bank AG | |
| 07.02.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 06.02.24 | Novartis Underweight | Barclays Capital | |
| 06.02.24 | Novartis Buy | UBS AG | |
| 05.02.24 | Roche Sell | Deutsche Bank AG | |
| 05.02.24 | Novartis Buy | Jefferies & Company Inc. | |
| 05.02.24 | Roche Neutral | UBS AG | |
| 02.02.24 | Roche Kaufen | DZ BANK | |
| 02.02.24 | Roche Equal Weight | Barclays Capital | |
| 02.02.24 | Roche Sell | Deutsche Bank AG | |
| 02.02.24 | Novartis Buy | Deutsche Bank AG | |
| 01.02.24 | Roche Neutral | UBS AG | |
| 01.02.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 01.02.24 | Roche Hold | Jefferies & Company Inc. | |
| 31.01.24 | Novartis Kaufen | DZ BANK | |
| 31.01.24 | Novartis Buy | UBS AG | |
| 31.01.24 | Novartis Buy | Jefferies & Company Inc. | |
| 30.01.24 | Roche Neutral | UBS AG | |
| 30.01.24 | Novartis Buy | UBS AG | |
| 30.01.24 | Roche Sell | Deutsche Bank AG | |
| 22.01.24 | Roche Hold | Deutsche Bank AG | |
| 19.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 16.01.24 | Novartis Buy | Jefferies & Company Inc. | |
| 16.01.24 | Roche Hold | Jefferies & Company Inc. | |
| 15.01.24 | Roche Neutral | UBS AG | |
| 15.01.24 | Novartis Buy | UBS AG | |
| 15.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 11.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 09.01.24 | Roche Equal Weight | Barclays Capital | |
| 09.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 08.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 08.01.24 | Novartis Neutral | UBS AG | |
| 05.01.24 | Novartis Buy | Deutsche Bank AG | |
| 03.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 03.01.24 | Novartis Buy | Jefferies & Company Inc. |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.